Congenital disorder of glycosylation
MONDO:0015286Congenital disorder of glycosylation (CDG) is a fast growing group of inborn errors of metabolism characterized by defective activity of enzymes that participate in glycosylation (modification of proteins and other macromolecules by adding and processing of oligosaccharide side chains). CDG is comprised of phenotypically diverse disorders affecting multiple systems including the central nervous system, muscle function, immunity, endocrine system, and coagulation. The numerous entities in this group are subdivided, based on the synthetic pathway affected, into disorder of protein N-glycosylation, disorder of protein O-glycosylation, disorder of multiple glycosylation, and disorder of glycosphingolipid and glycosylphosphatidylinositol anchor glycosylation.
Also known as: CDG, carbohydrate deficient glycoprotein syndrome, carbohydrate-deficient glycoprotein syndrome, congenital disorder of glycosylation, carbohydrate-deficient glycoprotein syndromes, congenital disorders of glycosylation
36 clinical trials for this condition and its sub-types, 7 tagged with Congenital disorder of glycosylation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Congenital disorder of glycosylation
-
Disorder of protein O-glycosylation 0 trials · 13 incl. sub-types
6 sub-types
- Myopathy caused by variation in FKRP 0 trials · 8 incl. sub-types Sub-types →
- Qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan 0 trials · 8 incl. sub-types Sub-types →
- Disorder of fucoglycosan synthesis 0 trials · 4 incl. sub-types Sub-types →
- Autosomal recessive limb-girdle muscular dystrophy type 2R1 1 trial
- Myopathy caused by variation in POMGNT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMGNT2 0 trials Sub-types →
-
Disorder of multiple glycosylation 0 trials · 9 incl. sub-types
19 sub-types
- GNE myopathy 3 trials
- Leukocyte adhesion deficiency type II 2 trials
- Reunion island Larsen syndrome 1 trial
- SLC35A2-congenital disorder of glycosylation 1 trial
- Congenital dyserythropoietic anemia type 2 1 trial
- Immunodeficiency 23 1 trial
- B4GALT1-congenital disorder of glycosylation 0 trials
- CCDC115-CDG 0 trials
- DK1-congenital disorder of glycosylation 0 trials
- DPM3-congenital disorder of glycosylation 0 trials Sub-types →
- MPDU1-congenital disorder of glycosylation 0 trials
- SLC35A1-congenital disorder of glycosylation 0 trials
- SRD5A3-congenital disorder of glycosylation 0 trials
- TMEM199-CDG 0 trials
- Congenital disorder of glycosylation type 1E 0 trials
- Congenital muscular dystrophy with intellectual disability and severe epilepsy 0 trials
- Defect in V-ATPase 0 trials
- Defect in conserved oligomeric Golgi complex 0 trials Sub-types →
- Developmental and epileptic encephalopathy, 50 0 trials
-
Congenital disorder of glycosylation type I 0 trials · 7 incl. sub-types
28 sub-types
- PMM2-congenital disorder of glycosylation 5 trials
- MPI-congenital disorder of glycosylation 1 trial
- PGM1-congenital disorder of glycosylation 1 trial
- ALG1-congenital disorder of glycosylation 0 trials
- ALG11-congenital disorder of glycosylation 0 trials
- ALG12-congenital disorder of glycosylation 0 trials
- ALG2-congenital disorder of glycosylation 0 trials Sub-types →
- ALG3-congenital disorder of glycosylation 0 trials
- ALG6-congenital disorder of glycosylation 1C 0 trials
- ALG8-congenital disorder of glycosylation 0 trials
- ALG9-congenital disorder of glycosylation 0 trials Sub-types →
- DDOST-congenital disorder of glycosylation 0 trials
- DK1-congenital disorder of glycosylation 0 trials
- DPAGT1-congenital disorder of glycosylation 0 trials
- DPM3-congenital disorder of glycosylation 0 trials Sub-types →
- MPDU1-congenital disorder of glycosylation 0 trials
- RFT1-congenital disorder of glycosylation 0 trials
- SRD5A3-congenital disorder of glycosylation 0 trials
- SSR3-CDG 0 trials
- SSR4-congenital disorder of glycosylation 0 trials
- STT3A-congenital disorder of glycosylation 0 trials
- STT3B-congenital disorder of glycosylation 0 trials
- Congenital disorder of glycosylation type 1E 0 trials
- Congenital disorder of glycosylation, type IAA 0 trials
- Congenital disorder of glycosylation, type ICC 0 trials
- Congenital muscular dystrophy with intellectual disability and severe epilepsy 0 trials
- Developmental and epileptic encephalopathy, 36 0 trials
- Developmental and epileptic encephalopathy, 50 0 trials
-
Disorder of protein N-glycosylation 0 trials · 7 incl. sub-types
26 sub-types
- PMM2-congenital disorder of glycosylation 5 trials
- MPI-congenital disorder of glycosylation 1 trial
- PGM1-congenital disorder of glycosylation 1 trial
- ALG1-congenital disorder of glycosylation 0 trials
- ALG11-congenital disorder of glycosylation 0 trials
- ALG12-congenital disorder of glycosylation 0 trials
- ALG2-congenital disorder of glycosylation 0 trials Sub-types →
- ALG3-congenital disorder of glycosylation 0 trials
- ALG6-congenital disorder of glycosylation 1C 0 trials
- ALG8-congenital disorder of glycosylation 0 trials
- ALG9-congenital disorder of glycosylation 0 trials Sub-types →
- DDOST-congenital disorder of glycosylation 0 trials
- DPAGT1-congenital disorder of glycosylation 0 trials
- MAN1B1-congenital disorder of glycosylation 0 trials
- MGAT2-congenital disorder of glycosylation 0 trials
- MOGS-congenital disorder of glycosylation 0 trials
- RFT1-congenital disorder of glycosylation 0 trials
- SLC39A8-CDG 0 trials
- SSR4-congenital disorder of glycosylation 0 trials
- ST3GAL3-congenital disorder of glycosylation 0 trials Sub-types →
- STT3A-congenital disorder of glycosylation 0 trials
- STT3B-congenital disorder of glycosylation 0 trials
- TMEM165-congenital disorder of glycosylation 0 trials
- Autism spectrum disorder - epilepsy - arthrogryposis syndrome 0 trials
- Congenital disorder of glycosylation type 1EE with or without immunodeficiency 0 trials
- Developmental and epileptic encephalopathy, 36 0 trials
-
Congenital disorder of glycosylation type II 0 trials · 3 incl. sub-types
26 sub-types
- Leukocyte adhesion deficiency type II 2 trials
- SLC35A2-congenital disorder of glycosylation 1 trial
- B4GALT1-congenital disorder of glycosylation 0 trials
- CCDC115-CDG 0 trials
- COG1-congenital disorder of glycosylation 0 trials
- COG4-congenital disorder of glycosylation 0 trials
- COG5-congenital disorder of glycosylation 0 trials
- COG6-congenital disorder of glycosylation 0 trials
- COG7-congenital disorder of glycosylation 0 trials
- COG8-congenital disorder of glycosylation 0 trials
- MGAT2-congenital disorder of glycosylation 0 trials
- MOGS-congenital disorder of glycosylation 0 trials
- SLC35A1-congenital disorder of glycosylation 0 trials
- SLC39A8-CDG 0 trials
- TMEM165-congenital disorder of glycosylation 0 trials
- TMEM199-CDG 0 trials
- Congenital disorder of glycosylation, type 2v 0 trials
- Congenital disorder of glycosylation, type IIaa 0 trials
- Congenital disorder of glycosylation, type IIbb 0 trials
- Congenital disorder of glycosylation, type IIcc 0 trials
- Congenital disorder of glycosylation, type IIq 0 trials
- Congenital disorder of glycosylation, type IIr 0 trials
- Congenital disorder of glycosylation, type IIw 0 trials
- Congenital disorder of glycosylation, type IIy 0 trials
- Congenital disorder of glycosylation, type IIz 0 trials
- Congenital disorder of glycosylation, type iit 0 trials
-
3 sub-types
-
2 sub-types
-
Larsen-like syndrome, B3GAT3 type 0 trials
-
8 sub-types
- CHIME syndrome 0 trials
- GM3 synthase deficiency 0 trials
- Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency 0 trials
- Hyperphosphatasia-intellectual disability syndrome 0 trials Sub-types →
- Intellectual disability, autosomal recessive 53 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 1 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 2 0 trials
- Multiple congenital anomalies-hypotonia-seizures syndrome 3 0 trials
Most studied deeper sub-types
-
New drug UX016 targets rare muscle disease
Disease control Recruiting nowThis early-stage trial tests UX016, a drug designed to help people with GNE myopathy, a rare genetic muscle-weakening disease. Researchers will give the drug or a placebo to 24 adults to see if it is safe and improves muscle strength. The study is not yet recruiting.
Phase 1/2 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Back surgery boost: Bone-Marrow injection may repair discs
Disease control Recruiting nowThis study tests whether adding a bone-marrow concentrate injection during routine back surgery helps the spinal disc heal better. About 90 adults with a herniated disc will get either surgery alone or surgery plus the injection. Researchers will use MRI scans and pain questionna…
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a common supplement help a rare disease? early trial begins
Disease control Recruiting nowThis early-stage trial is testing the safety of a dietary supplement called NMN in 8 people with a rare genetic disorder known as DHDDS-CDG, which affects movement and development. Participants will take 250 mg of NMN daily for 6 months, with an optional 12-month follow-up. The m…
Phase 1 • Sponsor: Eva Morava-Kozicz • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Hope for rare immune disease: new drug enters final testing
Disease control Recruiting nowThis study tests an experimental drug called AVTX-803 in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system and leads to frequent infections. The trial will compare the drug against a period without treatment to see…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental sugar therapy tested for ultra-rare immune disorder
Disease control Recruiting nowThis phase 3 study is testing the long-term safety and effectiveness of AVTX-803, a form of L-fucose, in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic disorder that weakens the immune system. Only 2 participants who completed a previous study are enro…
Phase 3 • Sponsor: AUG Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
NIH launches study to unravel mysteries of rare CDG diseases
Knowledge-focused Recruiting nowThis study from the National Human Genome Research Institute aims to better understand Congenital Disorders of Glycosylation (CDG), a group of rare genetic conditions that affect how the body attaches sugars to proteins and fats. Researchers will examine up to 200 participants, i…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Scientists track rare glycosylation disorders to unlock disease secrets
Knowledge-focused Recruiting nowThis study follows people with congenital disorders of glycosylation (CDG) — rare genetic conditions that affect how the body builds sugar chains on proteins. Researchers aim to track how the disease progresses over time, including its impact on organs and thinking abilities. By …
Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Major study aims to better measure muscular dystrophy progression
Knowledge-focused Recruiting nowThis 24-month observational study will follow up to 1000 people with certain types of muscular dystrophy (LGMD, DM2, and late-onset Pompe disease) aged 6-50. Researchers want to see if specific physical tests, like the North Star Assessment and a 100-meter walk, are good ways to …
Sponsor: Virginia Commonwealth University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC